Efficacy of sofos- buvir (SOF), daclatasvir (DCV) and weight-based ribavirin (RBV) for patients with Genotype 3 Hepatitis C and cirrhosis

Trial Profile

Efficacy of sofos- buvir (SOF), daclatasvir (DCV) and weight-based ribavirin (RBV) for patients with Genotype 3 Hepatitis C and cirrhosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs Daclatasvir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Nov 2017 New trial record
    • 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top